Floris Ilaria, García-González Víctor, Palomares Belen, Appel Kurt, Lejeune Beatrice
Preclinical & Clinical Development and Regulatory Affairs, Labo'Life France, 1 Rue François Bruneau, 44000 Nantes, France.
Innohealth Group, Madrid, Spain.
Int J Rheumatol. 2020 Jan 23;2020:1594573. doi: 10.1155/2020/1594573. eCollection 2020.
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease, which can cause cartilage and bone damages as well as pain and disability. In order to prevent disease progression, reduce pain, and major symptoms of RA, one good strategy consists in targeting proinflammatory cytokines that have the key role in the vicious circle of synovial inflammation and pain. The micro-immunotherapy medicine (MIM) 2LARTH® targets cytokines involved in inflammation.
The aim of the study is to evaluate the effect of the MIM compared to vehicle in an model of RA, induced in mice after immunization with articular bovine type II collagen.
Vehicle and MIM were dissolved in pure water (1 capsule in 100 ml) and 100 l was given by gavage daily for 14 days. To evaluate the severity of arthritis, wrist and ankle thickness was determined, paw edema was measured, and a clinical score from 0 to 4 was established. Furthermore, histological analysis was performed. To evaluate systemic inflammation, circulating levels of IL-1 and TNF- were measured by ELISA.
Ankle thickness was found to be significantly reduced in MIM-treated mice compared to vehicle-treated mice ( < 0.05) and compared to untreated me ( < 0.05) and compared to untreated me ( < 0.05) and compared to untreated me ( and TNF- were measured by ELISA. < 0.05) and compared to untreated me (.
The results indicate that the tested medicine reduces inflammation, histological, and clinical signs of RA in a CIA model.
类风湿关节炎（RA）是一种慢性炎症性关节疾病，可导致软骨和骨质破坏以及疼痛和残疾。为了预防疾病进展、减轻疼痛以及缓解RA的主要症状，一种有效的策略是针对在滑膜炎症和疼痛恶性循环中起关键作用的促炎细胞因子。微免疫疗法药物（MIM）2LARTH®靶向参与炎症的细胞因子。
本研究的目的是在经关节牛II型胶原免疫诱导的RA小鼠模型中，评估MIM与赋形剂相比的效果。
将赋形剂和MIM溶于纯水（100毫升中1粒胶囊），每天经口灌胃给予100微升，共14天。为评估关节炎的严重程度，测定腕关节和踝关节厚度，测量爪部水肿，并建立0至4分的临床评分。此外，进行了组织学分析。为评估全身炎症，通过酶联免疫吸附测定法（ELISA）测量白细胞介素-1（IL-1）和肿瘤坏死因子-α（TNF-α）的循环水平。
与赋形剂处理的小鼠相比，MIM处理的小鼠踝关节厚度显著降低（P<0.05），与未处理的小鼠相比也显著降低（P<0.05），通过ELISA测量白细胞介素-1（IL-1）和肿瘤坏死因子-α（TNF-α）。P<0.05），与未处理的小鼠相比（P<0.05）。
结果表明，在胶原诱导的关节炎（CIA）模型中，受试药物可减轻RA的炎症、组织学和临床症状。
